title: Evidence for an estrogen-like action of raloxifene upon the hypothalamic-pituitary unit: raloxifene inhibits luteinizing hormone secretion and stimulates prolactin secretion in ovariectomized female rats.
abstract: Selective estrogen receptor modulators (SERMs) constitute a new family of drugs with growing interest in the management of estrogen-associated pathology. Raloxifene is a SERM that is used to treat and prevent osteoporosis in postmenopausal women. The actions of raloxifene on bone, breast, uterus and serum cholesterol have been widely analyzed, but very few studies have been carried out to evaluate whether raloxifene has an estrogenic activity upon the hypothalamic-pituitary axis in the rat. For this purpose, adult female rats were ovariectomized or sham ovariectomized. One week later, the rats were implanted with intracardiac canullae and 24 h after injected daily with raloxifene (500 microg/rat/day) or vehicle for 5 days. One hour after the last injection, blood samples were obtained at 5 min intervals for a 3 h. period (10:00-13:00 h). Our results indicate that raloxifene inhibits the pulsatile nature of the post-ovariectomy hypersecretion of luteinizing hormone (LH) and increases prolactin (PRL) secretion in ovariectomized animals. These effects are suggestive of an estrogenic activity of raloxifene on LH and PRL secretion in ovariectomized females.
authors.affiliation: Department of Cell Biology, Physiology and Immunology, University of Córdoba School of Medicine, Córdoba, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Pinilla
authors.forename: L C
authors.initials: LC
authors.lastname: Gonzalez
authors.forename: M
authors.initials: M
authors.lastname: Tena-Sempere
authors.forename: E
authors.initials: E
authors.lastname: Aguilar
mesh_terms: D000818:Animals; D004967:Estrogens / Q000378:metabolism*; D030762:Estrous Cycle / Q000187:drug effects* / Q000502:physiology; D005246:Feedback / Q000187:drug effects / Q000502:physiology; D005260:Female; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects* / Q000378:metabolism; D007986:Luteinizing Hormone / Q000037:antagonists & inhibitors* / Q000097:blood / Q000378:metabolism; D010052:Ovariectomy; D011388:Prolactin / Q000819:agonists* / Q000097:blood / Q000378:metabolism; D020849:Raloxifene Hydrochloride / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology*
chemical_list: D004967:Estrogens; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D011388:Prolactin; D007986:Luteinizing Hormone